Latest / Deborah Kobylt LIVE / Deborah Kobylt LIVE_ Dr. Jeffrey Klausner, Infectious Disease Specialist, UCLA
Transcript
- 0:06Speaker 1: And we are live.
- 0:09Speaker 2: Hi, everybody, and thank you so much for joining us
- 0:11Speaker 2: today for a special edition of Debra Cobell Live. Joining
- 0:15Speaker 2: me now is the professor of medicine and public health
- 0:18Speaker 2: at UCLA with a special interest in epidemiology, Dr. Jeffrey Klausner. Doctor,
- 0:25Speaker 2: thank you so much for joining us.
- 0:27Speaker 1: Hi, very glad to be here on your show, Debra.
- 0:31Speaker 2: You've been very public about your thoughts about how you
- 0:34Speaker 2: feel about the direction that we're going as a country.
- 0:36Speaker 2: And you've been saying, you know what? Maybe we need
- 0:38Speaker 2: to get back into society. Why don't you explain a
- 0:42Speaker 2: little bit about your thoughts on how the country is
- 0:45Speaker 2: handling the coronavirus epidemic?
- 0:48Speaker 1: Yeah, so my epidemiology team at UCLA has been analyzing
- 0:53Speaker 1: the epidemics around the world since mid-January. And the first
- 0:58Speaker 1: reports came out in China. we started to track the
- 1:01Speaker 1: cases on a daily basis. And then we started to
- 1:04Speaker 1: track the new outbreaks in Japan, in Taiwan, in South Korea,
- 1:10Speaker 1: and then Iran. And we started to see some pretty
- 1:13Speaker 1: clear patterns emerge. And one of those patterns was that
- 1:17Speaker 1: with every epidemic, it went up and then it went down.
- 1:21Speaker 1: And that's what we normally see with infectious disease epidemics,
- 1:24Speaker 1: particularly those that are spread through the respiratory route. The
- 1:28Speaker 1: second important pattern we saw was that even though China
- 1:32Speaker 1: is a very large country, over 1.4 billion people, the
- 1:36Speaker 1: epidemic was highly localized in the city of Wuhan in
- 1:39Speaker 1: the Hubei province. So while they did have a very
- 1:43Speaker 1: severe lockdown, immediately prior to that lockdown, many people left Wuhan.
- 1:49Speaker 1: They went back to Beijing. They went to Guangdong. They
- 1:52Speaker 1: went to Shanghai. They went to other major cities. And
- 1:55Speaker 1: we did not see any subsequent large epidemics in those
- 1:59Speaker 1: other areas. Similarly, in Korea, the epidemic was highly localized
- 2:04Speaker 1: in the city, associated with the church and the contacts
- 2:09Speaker 1: of people in that church. But there was no additional
- 2:12Speaker 1: major spread in Seoul, for example. So it made me
- 2:15Speaker 1: think about an old adage that I learned when I
- 2:19Speaker 1: was an epidemiology student. that I learned from Professor Winkelstein
- 2:24Speaker 1: at UC Berkeley, the epidemic is local and we need
- 2:29Speaker 1: to actually look at the observational data. So certainly people
- 2:33Speaker 1: are very concerned with Northern Italy, for example, and that's devastating, right?
- 2:38Speaker 1: I mean, there's been a lot of problems there with
- 2:41Speaker 1: the hospitals, doctors have died, people have died, but we
- 2:45Speaker 1: have to look at what's going on in that setting.
- 2:48Speaker 1: So Northern Italy, traditionally, It's a very intimate culture. There's
- 2:53Speaker 1: a lot of close physical social contact. There's a lot
- 2:57Speaker 1: of kissing. There's a lot of hugging. And it's the
- 3:01Speaker 1: second oldest population in the world. So the first oldest
- 3:05Speaker 1: population is Japan. The second is actually Italy. So you
- 3:09Speaker 1: drop a new virus into a population that's never seen
- 3:13Speaker 1: the virus before in a very social population. in a
- 3:17Speaker 1: population with a lot of elderly and vulnerable people. And boom,
- 3:22Speaker 1: it takes off and there's a lot of medical and
- 3:26Speaker 1: serious consequences of death. Third thing that we identified.
- 3:30Speaker 2: Go ahead, no, go ahead. I have a lot of questions.
- 3:33Speaker 1: I'll wait for you to finish. Third thing that we
- 3:35Speaker 1: identified was that all these epidemics around the world are
- 3:39Speaker 1: occurring in a very narrow latitude or a tight band
- 3:43Speaker 1: of specific temperature and humidity conditions. The Chinese had described
- 3:48Speaker 1: about a month ago that the optimal transmission temperature was
- 3:53Speaker 1: about eight degrees centigrade or about 45, 46 degrees Fahrenheit.
- 3:58Speaker 1: And the optimal humidity was about 40 to 60%. And
- 4:03Speaker 1: then when we looked at those epidemics, we saw those
- 4:06Speaker 1: are the exact same mental temperature humidity conditions where those
- 4:11Speaker 1: epidemics really take off. Those three factors led me to
- 4:16Speaker 1: conclude that there are certain conditions that must occur for
- 4:20Speaker 1: an epidemic to really take off. There must be close
- 4:23Speaker 1: physical proximity, there must be certain types of social behaviors,
- 4:27Speaker 1: and there must be temperature and humidity conditions. It's just
- 4:32Speaker 1: like when you're trying to build a fire when you're camping.
- 4:35Speaker 1: You can get the kindling, you can get the wood,
- 4:38Speaker 1: but the conditions have to be right. Not every match
- 4:41Speaker 1: will ignite that fire.
- 4:44Speaker 2: Okay, let's back that up a little bit. You talked
- 4:46Speaker 2: about China, okay? Clearly, they were sequestered.
- 4:50Speaker 1: That's it.
- 4:50Speaker 2: Nobody out on the streets, in Wuhan in particular, they
- 4:54Speaker 2: just shut it down, as you know. South Korea we're
- 4:57Speaker 2: talking about. They did very similar there, and the cultures,
- 5:00Speaker 2: the people listened. In Italy, as we know, the cultures,
- 5:05Speaker 2: you know, the old, the young, everyone seems to live together,
- 5:09Speaker 2: but also it's an issue with their medical system. I
- 5:11Speaker 2: think they were overwhelmed. I was speaking with my own
- 5:14Speaker 2: family in Italy and primarily other than the big cities, right?
- 5:18Speaker 2: Other than Rome and Florence and Venice, these are small
- 5:22Speaker 2: villages and they're not equipped, right? To handle the onslaught
- 5:26Speaker 2: of people coming into the cities, going to the emergency rooms.
- 5:29Speaker 2: I mean, that's probably one of the reasons that they're
- 5:31Speaker 2: having such a problem, but here in America, right? There
- 5:34Speaker 2: is a, everyone is, whether it's Fauci, Governor Cuomo, our
- 5:39Speaker 2: governor here, Gavin Newsom, they're saying shut down at all costs,
- 5:44Speaker 2: sequester everyone, you're not walking in the park anymore. What
- 5:48Speaker 2: do you say to that? Perhaps we should just shut
- 5:50Speaker 2: it down until.
- 5:52Speaker 1: Well, I think the known and proven response to epidemics
- 5:57Speaker 1: is first identification and awareness. So identify what the cause is.
- 6:03Speaker 1: Identify how that cause contributes to transmissions. So we learned
- 6:08Speaker 1: actually the Chinese were very open and transparent with their
- 6:11Speaker 1: findings that this was a new coronavirus. They shared the
- 6:15Speaker 1: RNA sequence of that coronavirus in early January on the
- 6:18Speaker 1: World Wide Web. So everyone could verify, yes, this was
- 6:21Speaker 1: a new virus. That virus probably came from the bat
- 6:24Speaker 1: population where it's normally infects. And then it somehow jumped
- 6:30Speaker 1: from the bats to maybe a pangolin, which is a
- 6:33Speaker 1: type of intermediate virus. animal that people used for feasts
- 6:37Speaker 1: and for celebratory times, also for its medicinal properties. And
- 6:41Speaker 1: then it jumped into humans. So the first thing is
- 6:44Speaker 1: to identify the cause of the infection. And then the
- 6:49Speaker 1: second thing is to, okay, let's look at how it's spread.
- 6:52Speaker 1: So very early on, there was some misunderstanding. They thought
- 6:55Speaker 1: it was only spread by people going into the seafood
- 6:57Speaker 1: or the live animal market. Then they quickly recognized and
- 7:01Speaker 1: shared with everyone that no, this is actually spread human
- 7:03Speaker 1: to human. And that made people very concerned. Now you
- 7:07Speaker 1: have a new virus that is spread between. But then
- 7:12Speaker 1: once they identified that, they could actually tell people, well,
- 7:15Speaker 1: here's how you need to protect yourself. You need to
- 7:17Speaker 1: wash your hands. You need to cover your mouth when
- 7:21Speaker 1: you sneeze or cough. You need to stay away from
- 7:24Speaker 1: sick people. And if you're sick yourself, you need to
- 7:27Speaker 1: not go to work or not go to school. So
- 7:29Speaker 1: those are the phase two behavioral changes that people can
- 7:34Speaker 1: do on their own. Then quickly in China, they went
- 7:37Speaker 1: to phase three, which is these extensive social distancing interventions. Now,
- 7:42Speaker 1: whether those phase three interventions were needed, we may never
- 7:46Speaker 1: really know because perhaps those phase two were sufficient, but
- 7:50Speaker 1: because of great uncertainty and partly fueled by the exhaustive
- 7:58Speaker 1: pervasive media response to this, a lot of misinformation that's
- 8:03Speaker 1: been spread by the media, people's access to media. Go ahead,
- 8:08Speaker 1: I'm sorry.
- 8:09Speaker 2: I said there's a tremendous amount of misinformation.
- 8:11Speaker 1: But go ahead. People's access to media on their phones
- 8:14Speaker 1: nearly continuously, people sharing media with their friends through different
- 8:18Speaker 1: kind of social networks, that really fueled panic. And when
- 8:23Speaker 1: our political leaders are faced with a panicking population, they
- 8:28Speaker 1: panic themselves. And when they panic, they tend to overreact.
- 8:32Speaker 1: So what we've seen is an overreaction, the implementation of
- 8:37Speaker 1: these phase three interventions, strict social isolation and distancing that
- 8:43Speaker 1: may have never really been justified. I was reading, in.
- 8:47Speaker 2: Fact, today, someone sent me an article, you know, because
- 8:50Speaker 2: so many say, you know, this, come on, it's just
- 8:53Speaker 2: like the flu. So I was reading how the coronavirus cells,
- 8:58Speaker 2: they kind of have this right spiky ball and they
- 9:01Speaker 2: stick to the protein that's called ALE2 that's found on
- 9:05Speaker 2: the surface of our cells, right?
- 9:06Speaker 1: Is that correct? And it's just sort of- Well, actually
- 9:09Speaker 1: it's ACE2.
- 9:11Speaker 2: Okay, ACE2. Is that correct? And is that the reason why,
- 9:16Speaker 2: in fact, it can be more deadly or no? You're
- 9:19Speaker 2: the specialist.
- 9:20Speaker 1: Well, yeah, so it does appear it is more deadly
- 9:24Speaker 1: than influenza. So influenza kills about one out of a
- 9:27Speaker 1: thousand people who get infected. In the United States to date, 22,000
- 9:34Speaker 1: people have died from influenza, which means about 20 to
- 9:37Speaker 1: 30 million people in the United States have already been
- 9:41Speaker 1: infected with influenza this year only. That's about 10% of
- 9:45Speaker 1: the entire US population. So that's what also fueled some
- 9:49Speaker 1: of the early panic. They said, oh, well, if this
- 9:52Speaker 1: is more deadly than influenza, and spreads as easily, we're
- 9:57Speaker 1: clearly going to see a lot more death than influenza.
- 10:01Speaker 1: But it turns out this does not spread as easily
- 10:05Speaker 1: as influenza. It does spread to health care workers. It
- 10:10Speaker 1: does spread to household contacts. It does spread to social contacts.
- 10:15Speaker 1: But actually, for different reasons, perhaps we don't fully understand.
- 10:19Speaker 1: It's not as airborne for as long. It may not
- 10:22Speaker 1: last on surfaces for as long. And the infectious dose
- 10:27Speaker 1: that comes from someone who is infected may not be
- 10:30Speaker 1: as great. So the actual infectivity is not as high.
- 10:35Speaker 2: That's interesting. Go ahead.
- 10:38Speaker 1: One of the problems was that modelers, people said, okay, well,
- 10:41Speaker 1: there's this thing called a reproductive number. How efficiently does
- 10:44Speaker 1: it spread? That was estimated from the early phase of
- 10:48Speaker 1: the Wuhan epidemic before there was awareness, before there was
- 10:54Speaker 1: personal behavior change. We know that awareness and personal behavior
- 10:59Speaker 1: change change the reproductive number. It reduces the likelihood that
- 11:06Speaker 1: someone with infection can spread to another person.
- 11:09Speaker 2: By personal awareness, you're talking about space and washing your hands, right?
- 11:13Speaker 2: Because I also read that... when you wash your hands thoroughly, right,
- 11:17Speaker 2: for 20 seconds, it actually breaks down those lipid molecules.
- 11:22Speaker 2: Is that correct? And that's why it's so crucial to
- 11:24Speaker 2: wash your hands.
- 11:25Speaker 1: Yes?
- 11:25Speaker 2: No?
- 11:26Speaker 1: Deborah, you've clearly been doing your reading. I love that.
- 11:29Speaker 1: So yes.
- 11:30Speaker 2: I'm big on research. I read everything. So yeah, go ahead.
- 11:34Speaker 1: So this particular RNA virus has a lipid or a fatty...
- 11:39Speaker 1: kind of sphere around it, right? So the RNA, that
- 11:43Speaker 1: signature that tells the machinery how to reproduce, that's kind
- 11:50Speaker 1: of like the data code, the programming code, that lives
- 11:53Speaker 1: inside the shell. And the shell or envelope is actually
- 11:58Speaker 1: a fatty envelope. And that's why it actually makes it
- 12:00Speaker 1: so easy that it is degraded by any kind of
- 12:04Speaker 1: household soap, any kind of soap you may use to
- 12:07Speaker 1: wash your hands, any kind of sanitizing agent, which is
- 12:11Speaker 1: a very good thing in terms of reducing the spread
- 12:15Speaker 1: from person to person and decontaminating any surfaces, particularly in
- 12:20Speaker 1: the room in which someone is sick.
- 12:26Speaker 2: I guess that makes sense for all the run on,
- 12:28Speaker 2: you know, soap, hand sanitizer and toilet paper. I don't know,
- 12:31Speaker 2: but you're right. It does seem to work. So why
- 12:34Speaker 2: is it that one person will say it lasts on surfaces,
- 12:37Speaker 2: and by that I mean a doctor, Dr. Fauci, for example.
- 12:40Speaker 2: It will last on a surface up to so many hours.
- 12:42Speaker 2: Some will say up to so many days. I read
- 12:45Speaker 2: an article that said when they went into one of
- 12:47Speaker 2: the cruise ships, they found evidence of the coronavirus on
- 12:52Speaker 2: a surface 17 days later. I'm thinking, okay, what are
- 12:55Speaker 2: we supposed to believe?
- 12:56Speaker 1: I'm a journalist, I read everything.
- 12:57Speaker 2: You're a doctor, clearly you know mostly everything. But for
- 13:01Speaker 2: the average folks, We don't know what to believe, right?
- 13:05Speaker 2: We've got some states shutting down, some states allowing people
- 13:08Speaker 2: to go party on the beach.
- 13:10Speaker 1: What do we do? Right. I think part of the
- 13:12Speaker 1: problem is we've lost our science reporters. We've lost our
- 13:15Speaker 1: health reporters. With the explosion in media, everyone and their
- 13:19Speaker 1: brother and sister is becoming reporters. So you do your homework.
- 13:24Speaker 1: You do the research. You try to understand it. But
- 13:27Speaker 1: most people never take that Second, look behind the actual data,
- 13:32Speaker 1: or they're just promoting one report from one website to another.
- 13:36Speaker 1: If you actually look at the data, there's two aspects
- 13:40Speaker 1: to it. One is, yes, they detected the fingerprint of
- 13:45Speaker 1: the virus up to 17 days later. The same way
- 13:49Speaker 1: we can detect the fingerprint of the DNA from King Tut, 3,000, 5,000
- 13:55Speaker 1: years later, right? So the DNA fingerprint can last a
- 13:58Speaker 1: very long, long time. That doesn't mean that that is infectious.
- 14:04Speaker 1: So you have to actually see if you could grow
- 14:06Speaker 1: the virus from that specimen. So when they did that
- 14:09Speaker 1: analysis on the cardboard, on the plastic, on the stainless steel,
- 14:13Speaker 1: et cetera, they actually found they could only grow the
- 14:16Speaker 1: virus no more than six hours later. And the virus
- 14:21Speaker 1: started to drop down by half and half and half again,
- 14:25Speaker 1: it's half-life every couple hours. So there's been a big
- 14:31Speaker 1: misrepresentation of the science there, and people are not appreciating
- 14:35Speaker 1: the difference between the ability to grow the virus, which
- 14:38Speaker 1: means it potentially is infectious, and the ability to detect
- 14:43Speaker 1: the virus and find the fingerprint of the virus that's
- 14:46Speaker 1: been left over but is not infectious.
- 14:50Speaker 2: Doctors are saying, not particularly you, actually, but doctors are
- 14:53Speaker 2: saying we've got to flatten this curve. And you're saying
- 14:56Speaker 2: we did actually flatten the curve in New York. How
- 14:59Speaker 2: do we flatten the curve around the country so that
- 15:01Speaker 2: we can all be on one plane, if you will?
- 15:04Speaker 2: You know, my issue is I feel like there's no
- 15:06Speaker 2: consistent messages, right? You have the briefings every day coming
- 15:09Speaker 2: out of the White House. I'm thinking, OK, the president
- 15:11Speaker 2: would like this to end in time for the Easter Bunny.
- 15:14Speaker 2: You know, who do we believe, essentially?
- 15:18Speaker 1: Right. So you began your question with New York City
- 15:23Speaker 1: is actually seeing a flattening or maybe even declining cases.
- 15:28Speaker 2: But wait, let me interrupt you, doctor. But then the
- 15:30Speaker 2: governor there is saying, hey, I only got 400 ventilators.
- 15:33Speaker 2: I need, what does he say, 500,000 ventilators. I'm saying,
- 15:37Speaker 2: come on, how are we going to get that? It
- 15:39Speaker 2: just seems almost hysteria, in which case I'm led to say,
- 15:42Speaker 2: I don't know what to do. And I've been just
- 15:44Speaker 2: sitting in my house hoping this all goes away. I
- 15:46Speaker 2: won't let anybody near me. I throw my husband out
- 15:48Speaker 2: of the house. So what am I supposed.
- 15:50Speaker 1: To be doing, for example? Well, those are completely different questions.
- 15:54Speaker 1: I'm not sure which one you want to address.
- 15:57Speaker 2: Go down the line.
- 15:59Speaker 1: So as you started off your first question, you said
- 16:02Speaker 1: that the cases in New York City now have seemed
- 16:05Speaker 1: to stop increasing quickly and may actually be leveling off.
- 16:10Speaker 1: And that is true. So since the end of last
- 16:13Speaker 1: week and over the weekend, based on the New York
- 16:16Speaker 1: City case reports that's publicly available online, the number of
- 16:19Speaker 1: new cases have stopped increasing and may actually be leveling off.
- 16:25Speaker 1: New York City does a very good job of reporting
- 16:28Speaker 1: their data publicly by county or borough in New York City,
- 16:33Speaker 1: by age, by other risk factors. They also report the
- 16:38Speaker 1: number of people in the hospital, report the number of
- 16:40Speaker 1: people in an intensive care unit, New York City right
- 16:43Speaker 1: now has one of the finest examples of epidemiological infectious
- 16:48Speaker 1: disease reporting in the country. And because of that data,
- 16:52Speaker 1: we can see that the cases might be leveling off.
- 16:57Speaker 1: And it's interesting that leveling has occurred before the Sunday
- 17:01Speaker 1: night shutdown. So a lot of the arguments against the
- 17:07Speaker 1: shortening of the shutdowns have been, well, how do you
- 17:10Speaker 1: know they didn't work? Right. You know, they're associated. They're correlated.
- 17:16Speaker 1: But how do you know they're not causal? And we're
- 17:19Speaker 1: at too great a risk. We're panicking too much that
- 17:22Speaker 1: if we shorten our shutdown, you might be wrong. But
- 17:26Speaker 1: I say now look in New York City. Their shutdown
- 17:28Speaker 1: officially didn't start till Sunday night. Cases were dropping already
- 17:32Speaker 1: before the shutdown began. The second question you asked was, OK,
- 17:37Speaker 1: what do I do? What do I need to do?
- 17:38Speaker 1: I'm locked up in my house. I'm driving my husband crazy.
- 17:41Speaker 1: So people need to remember.
- 17:42Speaker 2: I didn't say that, but go ahead.
- 17:45Speaker 1: People need to know now that there's more testing capacity
- 17:49Speaker 1: available at all major medical centers, certainly in California and
- 17:54Speaker 1: in many urban areas around the country. If they call
- 17:58Speaker 1: their doctor and they have any symptoms of cough, fever,
- 18:02Speaker 1: shortness of breath, or sore throat or headache, any of
- 18:06Speaker 1: those typical flu-like or cold symptoms, Their doctor most probably
- 18:11Speaker 1: can arrange for them to get a test. So testing
- 18:14Speaker 1: is very important for medical management purposes.
- 18:18Speaker 2: Where would you have to go to the hospital for
- 18:21Speaker 2: us to be able to track the epidemic?
- 18:23Speaker 1: So knowing where cases are occurring and knowing where cases
- 18:27Speaker 1: are not occurring.
- 18:29Speaker 2: So I'm not feeling well, let's say, and if I'm
- 18:32Speaker 2: getting a fever and I want to get a test,
- 18:33Speaker 2: we all know that you have to contact your doctor first,
- 18:36Speaker 2: but I'm reading that there are not enough tests or
- 18:38Speaker 2: is that not the case? Let's say California, let's come
- 18:41Speaker 2: back here to California. Would there be enough tests and
- 18:44Speaker 2: where would I go? Would I go to my local
- 18:45Speaker 2: hospital or my local doctor's office?
- 18:48Speaker 1: Well, I think, you know, Los Angeles just launched this,
- 18:53Speaker 1: you know, Get Tested LA program. And on this Get
- 18:57Speaker 1: Tested LA program, people can contact in city of Los Angeles,
- 19:03Speaker 1: which has over 4 million residents and they will provide
- 19:07Speaker 1: access to testing. New York City and New York State
- 19:11Speaker 1: has one of the largest testing programs in the country
- 19:15Speaker 1: doing thousands and thousands of tests a day. So increasingly
- 19:20Speaker 1: testing is becoming available. We are working with the FDA
- 19:24Speaker 1: and other test manufacturers to hopefully very soon be able
- 19:29Speaker 1: to provide at-home collection.
- 19:31Speaker 2: I love that.
- 19:33Speaker 1: They could collect a swab, put that swab in the tube,
- 19:37Speaker 1: send that off to a high-complexity validated laboratory, and then
- 19:43Speaker 1: go online and learn their test result. We're moving toward that.
- 19:48Speaker 1: We're not moving as quickly as we could. The FDA
- 19:52Speaker 1: has been, you know, cautious and they've, you know, said
- 19:57Speaker 1: home testing, which is different than home collection, but home
- 20:01Speaker 1: collection right now has not been validated, but we're working
- 20:04Speaker 1: with the FDA to, to validate that. And that would
- 20:07Speaker 1: certainly be a breakthrough in access to testing for people.
- 20:11Speaker 2: Where are we in some of the antivirals that we're
- 20:14Speaker 2: all talking about? I read, again, that some of them
- 20:17Speaker 2: are in clinical trials. Some of them are being used
- 20:20Speaker 2: by doctors. Let's talk about them. I believe there's two
- 20:23Speaker 2: or three in particular, right, that are hopeful? Right.
- 20:26Speaker 1: So the two best treatments we have right now, one
- 20:29Speaker 1: is called Remdesivir with an R.
- 20:31Speaker 2: Thank you for saying that because I couldn't pronounce it.
- 20:33Speaker 2: So thank you.
- 20:34Speaker 1: So remdesivir was originally developed by a drug company to
- 20:39Speaker 1: treat Ebola. It seemed to have some activity potentially in Ebola.
- 20:44Speaker 1: It was also studied in other coronaviruses and the original
- 20:47Speaker 1: SARS coronavirus and animal models also showed some activity. It's
- 20:52Speaker 1: been available on what we call a compassionate use basis,
- 20:55Speaker 1: which means a one-on-one basis between the doctor and the
- 20:59Speaker 1: company until last week. Then this weekend, the company made
- 21:04Speaker 1: it available on what's called expanded access, which makes it
- 21:08Speaker 1: easier and more available. So most patients, at least in
- 21:12Speaker 1: California and probably other major urban areas, if they're sick
- 21:18Speaker 1: enough to be in the hospital and they're sick enough
- 21:20Speaker 1: to require more significant therapy, would probably, depending on where
- 21:29Speaker 1: they are, of course, have that drug made available to them.
- 21:33Speaker 1: The company is working very quickly, very closely with the
- 21:36Speaker 1: FDA to make their clinical trial results useful to gain
- 21:41Speaker 1: approval for that medication. It's an antiviral medication that doctors
- 21:48Speaker 1: know is very safe. Doctors are very familiar with this
- 21:51Speaker 1: kind of antiviral medication. It's got a similar kind of
- 21:55Speaker 1: activity to the medicines we use to treat HIV. We've
- 21:58Speaker 1: been treating HIV effectively since 1996. So this is not
- 22:04Speaker 1: a particularly new type of medication. It's just never been
- 22:07Speaker 1: used for this specific indication. The second type of medication
- 22:13Speaker 1: is called an immune blocker. So a lot of people
- 22:17Speaker 1: with certain kinds of diseases these days, like bad arthritis
- 22:21Speaker 1: or psoriasis, or those terrible commercials you see all the
- 22:24Speaker 1: time on television about ask your doctor for this, you know, antibody,
- 22:29Speaker 1: et cetera. And they show people running through the fields.
- 22:32Speaker 1: That's essentially the same kind of medicine, this, you know,
- 22:34Speaker 1: type of model.
- 22:37Speaker 2: What's that one called? Is that one the hydroxy? I'm
- 22:41Speaker 2: not quite good with the names.
- 22:42Speaker 1: Could you say that? We will get to that one next.
- 22:46Speaker 2: So that's number three.
- 22:47Speaker 1: Okay. This one is a monoclonal antibody given by infusion.
- 22:51Speaker 1: So it has to be injected into people. The Chinese
- 22:55Speaker 1: have had some experience with that. The reports I've seen
- 22:57Speaker 1: directly from the Chinese scientists looks very promising. It's currently
- 23:01Speaker 1: in trials right now in the United States. The good
- 23:05Speaker 1: thing is that it's already approved and used for arthritis.
- 23:09Speaker 1: So the FDA has said this medication is safe. And
- 23:13Speaker 1: now doctors, once they know the clinical evidence, can just
- 23:16Speaker 1: repurpose this for more sick individuals. Unfortunately, its production is
- 23:23Speaker 1: still somewhat limited and its availability is not widespread, but
- 23:28Speaker 1: we are using it in our sickest patients. It is
- 23:32Speaker 1: called an interleukin six blocker.
- 23:36Speaker 2: Interleukin six blocker.
- 23:38Speaker 1: Okay. Right. And then the third drug, which you've heard
- 23:41Speaker 1: about from the president of the United States and others
- 23:44Speaker 1: is a malaria medication called, um, hydrochloroquine or hydroxychloroquine. And
- 23:53Speaker 1: hydroxychloroquine has been used for decades to treat malaria, particularly
- 23:58Speaker 1: in Central America. It can't be used in Africa or
- 24:01Speaker 1: Asia because most of malaria is already resistant to chloroquine.
- 24:05Speaker 1: Then it was repurposed to use as an arthritis medication
- 24:09Speaker 1: under the brand name Plaquenil. And for patients with chronic arthritis,
- 24:13Speaker 1: it tends to be actually very favorable. So some scientists thought, though,
- 24:18Speaker 1: it may have antiviral effect. And there was some demonstration
- 24:23Speaker 1: of antiviral effect in the test tube. But now two
- 24:26Speaker 1: studies have shown that there's no benefit to hydroxychloroquine, this
- 24:33Speaker 1: anti-malaria drug. We're still waiting for additional studies. But most
- 24:37Speaker 1: doctors now who read those studies are not confident in
- 24:42Speaker 1: the efficacy of hydroxychloroquine. So we're advising people not to
- 24:47Speaker 1: buy hydroxychloroquine and not to use hydroxychloroquine.
- 24:52Speaker 2: Right. They were combining that with what, Zithromax?
- 24:54Speaker 1: I mean, it was a comedy. So in that one
- 24:56Speaker 1: study that was reported, which was a combination of an
- 25:00Speaker 1: antibiotic called the Zithromax and the anti-malaria or anti-inflammatory hydroxychloroquine,
- 25:07Speaker 1: if you actually properly analyze the data, there was no
- 25:12Speaker 1: difference for, for some reason, the researchers throughout the people
- 25:18Speaker 1: who did not survive until the end point, which, you know,
- 25:22Speaker 1: some might argue is the best way to analyze the data. Okay. Doctor.
- 25:26Speaker 2: So where do you see us? Do you say that
- 25:28Speaker 2: we obviously we should keep our distance just like we
- 25:32Speaker 2: are here in this interview, washing our hands, but what
- 25:35Speaker 2: about self-isolation and quarantining ourselves? How would you like to
- 25:39Speaker 2: see this rollout?
- 25:41Speaker 1: So let's just get the terminology correct for a minute.
- 25:45Speaker 1: So isolation means the restriction of movement with someone with infection.
- 25:52Speaker 1: So when someone has COVID-19 infection, they're isolated. When someone
- 25:56Speaker 1: has tuberculosis, they're isolated. And that means they're removed from
- 26:00Speaker 1: social contact. They may be in the hospital, put in
- 26:02Speaker 1: a special room, et cetera. Quarantine is a term that's
- 26:06Speaker 1: used when someone is exposed, but they're not infected. So
- 26:09Speaker 1: if you're a healthcare worker, if you're a first responder,
- 26:13Speaker 1: if you're returning from an endemic area, like Europe or Asia,
- 26:20Speaker 1: you were put in quarantine. So you weren't infected, but
- 26:23Speaker 1: you were just put away and observed until you develop symptoms.
- 26:27Speaker 1: Symptoms typically develop after about five to seven days, but
- 26:32Speaker 1: we're being very conservative and we had a quarantine period
- 26:35Speaker 1: of up to 14 days. We found that if people
- 26:38Speaker 1: did not develop symptoms by 14 days, it was very,
- 26:41Speaker 1: very unlikely that they actually developed infection. So what we
- 26:48Speaker 1: need to move toward now that we have testing available,
- 26:51Speaker 1: we have better data at the local level, is a
- 26:55Speaker 1: local response that depends on testing and finding cases, finding positives,
- 27:01Speaker 1: isolating those positives, notifying any contacts within the family or
- 27:06Speaker 1: social group or business contacts that may have been exposed.
- 27:11Speaker 1: making sure those exposed contacts are tested. If they're positive,
- 27:16Speaker 1: isolating those individuals, treating those individuals based on the severity
- 27:20Speaker 1: of disease. If they're negative, they can be quarantined for
- 27:24Speaker 1: a short amount of time. And now with tests, we
- 27:27Speaker 1: can actually shorten the duration of quarantine from the 14 days,
- 27:32Speaker 1: probably to as short as five days. That if you
- 27:35Speaker 1: test negative after exposure, five days, Some people say seven days,
- 27:41Speaker 1: but five to seven days, you're probably good to go
- 27:45Speaker 1: and we're not infected.
- 27:47Speaker 2: How are we doing with ventilators and other kinds of
- 27:50Speaker 2: equipment like masks that so many of our first responders
- 27:52Speaker 2: claim there's not enough of?
- 27:55Speaker 1: Well, there's definitely not enough masks. And if we were
- 27:58Speaker 1: to see the type of epidemic that some people predicted
- 28:01Speaker 1: where the entire country was impacted at the same time
- 28:05Speaker 1: or entire city was impacted at the same time, we
- 28:09Speaker 1: would certainly be short of hospital beds and ventilators. And
- 28:15Speaker 1: most of the time, our intensive care units are full.
- 28:18Speaker 1: They're at capacity. We've tried to maintain our ability to
- 28:25Speaker 1: treat people by limiting elective surgeries. Fortunately, the influenza epidemic
- 28:30Speaker 1: in 2019-20 is essentially over. Los Angeles County declared yesterday
- 28:36Speaker 1: that the influenza epidemic is over and the absence of influenza,
- 28:42Speaker 1: while not completely gone, the number of new cases is
- 28:45Speaker 1: relatively low and that frees up a lot of hospital
- 28:48Speaker 1: beds and a lot of intensive care unit beds and ventilators.
- 28:53Speaker 2: What about our governor lifting and our mayor lifting here
- 28:57Speaker 2: in Los Angeles? You know, you really can't go out
- 29:00Speaker 2: hiking in a park. You can't, I think they sealed
- 29:03Speaker 2: off some of the parking by the beach. Now, that
- 29:05Speaker 2: was my big thing. I would just go to the
- 29:07Speaker 2: beach and get on my bike and go. I wasn't
- 29:09Speaker 2: near anybody, but now I can't even do that. When
- 29:12Speaker 2: do you think they should be lifting that so we
- 29:14Speaker 2: can get out and get fresh air, but make sure
- 29:16Speaker 2: we're not infecting anyone else if we're asymptomatic?
- 29:20Speaker 1: I'm hoping they'll lift that as soon as possible. I
- 29:22Speaker 1: think people are looking at the data on an ongoing basis.
- 29:25Speaker 1: I think there's been somewhat of a groundswell of alternative opinion.
- 29:33Speaker 1: from very well-known epidemiologists at Stanford, people at Yale University,
- 29:40Speaker 1: Nobel laureates, people from other academic centers who are starting
- 29:45Speaker 1: to call for a rethinking of our approach and a
- 29:49Speaker 1: reassessment of our current strategy.
- 29:53Speaker 2: Okay, doctors. Thank you very, very much for joining us.
- 29:57Speaker 2: I mean, any parting words that you'd like to tell
- 29:59Speaker 2: us and people out in the public who are confused,
- 30:02Speaker 2: they listen to the briefings, they don't know who to
- 30:04Speaker 2: listen to, the doctor or the president. They read online
- 30:07Speaker 2: and it's a tremendous amount of misinformation so that we
- 30:11Speaker 2: can go by the way of China, according to how
- 30:14Speaker 2: they say it went, and South Korea that there's, you know,
- 30:17Speaker 2: that we level this off.
- 30:19Speaker 1: Well, I think people should be reassured. I think they
- 30:22Speaker 1: should be confident in the fact that those epidemics went
- 30:26Speaker 1: up and they went down. I think they should be
- 30:29Speaker 1: reassured by the absence of epidemics in most places around
- 30:34Speaker 1: the country. I think they should be reassured by the
- 30:37Speaker 1: increased availability of testing. I think they should be reassured
- 30:41Speaker 1: by the new treatments that we have increasingly available. Some
- 30:45Speaker 1: are still undergoing testing, but they are being used. And
- 30:50Speaker 1: I think they should be reassured that this intensive social
- 30:57Speaker 1: distancing is going to be time limited. We will get
- 31:00Speaker 1: back to school. We will get back to work very soon.
- 31:04Speaker 1: There's a lot of debate about how soon, but I
- 31:08Speaker 1: am pushing hard for sooner than later.
- 31:12Speaker 2: Right. You're pushing for the end of the month. I'm
- 31:14Speaker 2: not sure that's going to happen. Just finally, one more
- 31:16Speaker 2: question for you. all those people who may be losing
- 31:19Speaker 2: their jobs, all those people who then could possibly lose
- 31:21Speaker 2: their health insurance. And let's talk about there could be
- 31:24Speaker 2: an uptick in depression and all sorts of other issues
- 31:28Speaker 2: if we don't eventually get ourselves back on track. Can
- 31:31Speaker 2: you address that? Well, that's the real consequences of panic
- 31:36Speaker 2: and overreaction. And so I'm hoping there'll be some accountability
- 31:42Speaker 2: for that. But we definitely need to, you know, protect
- 31:45Speaker 2: low-income wage workers.
- 31:46Speaker 1: We need to, you know, develop resources for them. I mean,
- 31:50Speaker 1: there have been some, you know, policy interventions to, you know,
- 31:54Speaker 1: put a halt on anyone, you know, being evicted or,
- 31:58Speaker 1: you know, people losing their benefits. But, you know, that
- 32:03Speaker 1: is a somewhat, you know, expected consequence of panic and overreaction.
- 32:11Speaker 1: We also will have to continue to protect the most
- 32:13Speaker 1: vulnerable and people living in, you know, assisted living or
- 32:18Speaker 1: nursing homes. We know that that is a highly susceptible population,
- 32:25Speaker 1: both for potential infection and consequences of infection. So we
- 32:31Speaker 1: saw what happened to the rate of an elderly, fragile population,
- 32:35Speaker 1: but we can do interventions in those nursing homes and
- 32:38Speaker 1: assisted living situations. We can have- I mean, look at Washington.
- 32:41Speaker 1: monitored for fever.
- 32:42Speaker 2: Yeah, look at Washington. They very effectively brought that curve down.
- 32:47Speaker 1: In the state of Washington, yes. And that's because, again,
- 32:50Speaker 1: every epidemic is local. There's been no evidence of any
- 32:53Speaker 1: generalized spread to the overall population like influenza. That's a
- 32:57Speaker 1: key difference between the epidemiology of this infection COVID-19 and
- 33:02Speaker 1: the epidemiology of influenza. They are different.
- 33:08Speaker 2: Thank you very much, Dr. Jeffrey Klausner. If people actually
- 33:10Speaker 2: have questions for you, they want to contact you, go
- 33:12Speaker 2: on your page. How can they get in touch with you?
- 33:16Speaker 1: Well, there's, you know, information about me on the UCLA
- 33:19Speaker 1: website and my, you know, email is publicly available and
- 33:25Speaker 1: be happy to answer any questions in the future.
- 33:28Speaker 2: I appreciate it very much, doctor. Hopefully we'll, be talking
- 33:31Speaker 2: to again as this progresses and hopefully on the downside.
- 33:35Speaker 2: So thank you very, very much. And thank you everybody
- 33:37Speaker 2: for joining us for this special edition of Debra Cobelt
- 33:40Speaker 2: Live coming to you from my kitchen. So like anyone else, right?
- 33:44Speaker 2: We were looking for the right location here and the
- 33:47Speaker 2: kitchen seems to be working. So thank you, Dr. Klauser.
- 33:50Speaker 1: And thank you. You're welcome. Bye-bye.
- 33:53Speaker 2: Bye-bye for joining us on Debra Cobelt Live. And we'll
- 33:55Speaker 2: see you next time. You can find us of course
- 33:57Speaker 2: on Facebook, I think the doctor left us Facebook, YouTube, Instagram, iHeartRadio,
- 34:04Speaker 2: Apple Podcasts, and anywhere else that you get your podcasts.
- 34:06Speaker 2: So thank you very much for joining us and we'll
- 34:08Speaker 2: see you next time.
- 34:08Speaker 1: Bye-bye.